Aberrant glycosylation associated with enzymes as cancer biomarkers
暂无分享,去创建一个
[1] R. Johnson. Letter: Primary non-function in cadaver kidney transplants. , 1975, Lancet.
[2] R. Bast,et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.
[3] Josef Korinek,et al. Proceedings of the American Society of Clinical Oncology , 1982 .
[4] M. Duffy,et al. Multiple forms of plasminogen activator in human breast tumors. , 1985, Cancer research.
[5] S. Hakomori,et al. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. , 1985, Cancer research.
[6] M. Duffy,et al. Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.
[7] M. Schmitt,et al. UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCER , 1989, The Lancet.
[8] M. Du,et al. Fucosyltransferases: Differential plasma and tissue alterations in hepatocellular carcinoma and cirrhosis , 1991, Hepatology.
[9] T. Hada,et al. Enzymatic basis of sugar structures of α‐fetoprotein in hepatoma and hepatoblastoma cell lines: Correlation with activities of α1–6 fucosyltransferase and N‐acetylglucosaminyltransferases III and V , 1992, International journal of cancer.
[10] M. Fukuda. Possible roles of tumor-associated carbohydrate antigens. , 1996, Cancer research.
[11] D. Chan,et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] H. Inoue,et al. α‐2,3‐sialyltransferase type 3N and α‐1,3‐fucosyltransferase type VII are related to sialyl Lewisx synthesis and patient survival from lung carcinoma , 1997 .
[13] H. Inoue,et al. alpha-2,3-Sialyltransferase type 3N and alpha-1,3-fucosyltransferase type VII are related to sialyl Lewis(x) synthesis and patient survival from lung carcinoma. , 1997, Cancer.
[14] O. Nilsson,et al. Summary Report on the ISOBM TD-6 Workshop: Analysis of 20 Monoclonal Antibodies against Sialyl Lewisa and Related Antigens , 1998, Tumor Biology.
[15] Keiichiro Suzuki,et al. High expression of α‐1‐6 fucosyltransferase during rat hepatocarcinogenesis , 1998 .
[16] L. Hornez,et al. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. , 1998, Cancer research.
[17] High expression of alpha-1-6 fucosyltransferase during rat hepatocarcinogenesis. , 1998, International journal of cancer.
[18] J. Dennis,et al. Glycoprotein glycosylation and cancer progression. , 1999, Biochimica et biophysica acta.
[19] R. Poulsom,et al. An α2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas , 1999 .
[20] R. Poulsom,et al. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. , 1999, Glycobiology.
[21] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] N. Tanaka,et al. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. , 1999, Internal medicine.
[23] T. Ørntoft,et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. , 1999, Clinical chemistry.
[24] P. Schlag,et al. Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases , 2000, Gut.
[25] J. Dennis,et al. Suppression of tumor growth and metastasis in Mgat5-deficient mice , 2000, Nature Medicine.
[26] Immunogenicity of glycolipids. , 2000, Clinical reviews in allergy & immunology.
[27] J. Portoukalian. Immunogenity of glycolipids , 2000 .
[28] P. Schlag,et al. Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas. , 2001, Cancer research.
[29] S. Satomura,et al. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. , 2001, Clinica chimica acta; international journal of clinical chemistry.
[30] Clinical significance of ST3Gal IV expression in human renal cell carcinoma. , 2002, Oncology reports.
[31] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Wolchok,et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] N. Hayashi,et al. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. , 2003, Cancer research.
[34] Pauline M Rudd,et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. , 2003, Glycobiology.
[35] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[36] P. Schlag,et al. Clinical Relevance of Sialyltransferases ST6GAL-I and ST3GAL-III in Gastric Cancer , 2003, Oncology.
[37] A. Díaz,et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. , 2003, Clinical immunology.
[38] M. Pierce,et al. N-Acetylglucosaminyltransferase V Expression Levels Regulate Cadherin-associated Homotypic Cell-Cell Adhesion and Intracellular Signaling Pathways* , 2003, Journal of Biological Chemistry.
[39] R. Contreras,et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer–based total serum protein glycomics , 2004, Nature Medicine.
[40] G. Ritter,et al. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse , 2004, Cancer Immunology, Immunotherapy.
[41] Minoru Fukuda,et al. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. , 2004, Glycobiology.
[42] Baruch S Blumberg,et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] J. Esko,et al. The sweet and sour of cancer: glycans as novel therapeutic targets , 2005, Nature Reviews Cancer.
[44] Mary Ann Comunale,et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. , 2005, Journal of hepatology.
[45] C. Bertozzi,et al. Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.
[46] Robert Camp,et al. β1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast Carcinoma , 2005, Clinical Cancer Research.
[47] Mary Ann Comunale,et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. , 2006, Journal of proteome research.
[48] A. Nicolas,et al. UDP-N-Acetyl-d-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[49] Terence C W Poon,et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. , 2006, Journal of proteome research.
[50] A. Furlan,et al. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. , 2006, Glycobiology.
[51] R. Contreras,et al. N‐glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus , 2007, Hepatology.
[52] D. Chan,et al. Enzymes and related proteins as cancer biomarkers: a proteomic approach. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[53] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] N. Hayashi,et al. A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. , 2007, Glycobiology.
[55] Y. Mechref,et al. Alterations in the serum glycome due to metastatic prostate cancer. , 2007, Journal of proteome research.
[56] H. Yoo,et al. Functional Proteomics Study Reveals That N-Acetylglucosaminyltransferase V Reinforces the Invasive/Metastatic Potential of Colon Cancer through Aberrant Glycosylation on Tissue Inhibitor of Metalloproteinase-1*S , 2008, Molecular & Cellular Proteomics.
[57] J. Michalski,et al. Glycoproteomics and glycomics investigation of membrane N‐glycosylproteins from human colon carcinoma cells , 2008, Proteomics.
[58] Pauline M. Rudd,et al. Glycosylation Changes on Serum Glycoproteins in Ovarian Cancer May Contribute to Disease Pathogenesis , 2009, Disease markers.
[59] Chung-Yi Wu,et al. Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer , 2008, Proceedings of the National Academy of Sciences.
[60] B. Milutinovic,et al. Glycoforms of CA125 antigen as a possible cancer marker. , 2008, Cancer biomarkers : section A of Disease markers.
[61] D. Dinulescu,et al. Focused glycomic analysis of the N‐linked glycan biosynthetic pathway in ovarian cancer , 2008, Proteomics.
[62] Mark Liebow,et al. Association of Single Nucleotide Polymorphisms in Glycosylation Genes with Risk of Epithelial Ovarian Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.
[63] K. Aoki,et al. Targeted glycoproteomic identification of biomarkers for human breast carcinoma. , 2008, Journal of proteome research.
[64] Yehia Mechref,et al. Glycomic profiling of invasive and non-invasive breast cancer cells , 2009, Glycoconjugate Journal.
[65] W. Jiang,et al. Prognostic utility of glycosyltransferase expression in breast cancer. , 2008, Cancer genomics & proteomics.
[66] Yehia Mechref,et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. , 2008, Clinical chemistry.
[67] Pauline M Rudd,et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. , 2008, Glycobiology.
[68] R. Dwek,et al. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. , 2008, Glycobiology.
[69] K. Murayama,et al. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects , 2008, International journal of cancer.
[70] D. Chan,et al. Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. , 2009, Expert opinion on medical diagnostics.
[71] K. Yonemori,et al. Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. , 2009, Journal of proteome research.
[72] M. Ohue,et al. Comprehensive clinico-glycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells. , 2009, Journal of proteome research.
[73] K. Ohtsubo,et al. Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. , 2009, Carbohydrate research.
[74] Mary Ann Comunale,et al. Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma , 2009, Cancer Epidemiology Biomarkers & Prevention.
[75] Yin-kun Liu,et al. Lectin‐based glycoproteomics to explore and analyze hepatocellular carcinoma‐related glycoprotein markers , 2009, Electrophoresis.
[76] Mary Ann Comunale,et al. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. , 2009, Journal of proteome research.
[77] Lori J Sokoll,et al. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. , 2009, Journal of proteome research.
[78] R. Seruca,et al. The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. , 2009, Human molecular genetics.
[79] E. Osinaga,et al. Expression of UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 in Gastric Mucosa, Intestinal Metaplasia, and Gastric Carcinoma , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[80] M. Hollingsworth,et al. The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-Lectin Sandwich Arrays* , 2009, Molecular & Cellular Proteomics.
[81] Joris Delanghe,et al. GlycoFibroTest Is a Highly Performant Liver Fibrosis Biomarker Derived from DNA Sequencer-based Serum Protein Glycomics*S , 2009, Molecular & Cellular Proteomics.
[82] Wenqiang Song,et al. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry , 2010, BMC Cancer.
[83] D. Chan,et al. The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[84] S. Hakomori,et al. N‐glycosylation status of β‐haptoglobin in sera of patients with colon cancer, chronic inflammatory diseases and normal subjects , 2009, International journal of cancer.
[85] S. Baba,et al. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. , 2010, Glycobiology.
[86] Susan J Fisher,et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. , 2010, Clinical chemistry.
[87] H. Imamura,et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC , 2010, Journal of Gastroenterology.
[88] S. Pinder,et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis , 2010, Glycobiology.
[89] Yusuke Nakamura,et al. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. , 2010, Cancer research.
[90] R. Peracaula,et al. α2,3-Sialyltransferase ST3Gal III Modulates Pancreatic Cancer Cell Motility and Adhesion In Vitro and Enhances Its Metastatic Potential In Vivo , 2010, PloS one.
[91] J. Ko,et al. Comparative quantitation of aberrant glycoforms by lectin-based glycoprotein enrichment coupled with multiple-reaction monitoring mass spectrometry. , 2010, Analytical chemistry.
[92] Sudhir Srivastava,et al. A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[93] S. Köklü,et al. Diagnostic and Prognostic Validity of Golgi Protein 73 in Hepatocellular Carcinoma , 2010, Digestion.
[94] L. Wells,et al. Identification of candidate biomarkers with cancer‐specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis , 2010, Proteomics.
[95] N-glycomic changes in human breast carcinoma MCF-7 and T-lymphoblastoid cells after treatment with herceptin and herceptin/Lipoplex. , 2010, Journal of proteome research.
[96] M. Hollingsworth,et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. , 2010, Cancer research.
[97] M. Di Michele,et al. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. , 2010, Journal of proteomics.
[98] S. Du,et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma , 2010, Gut.
[99] Generation of antibodies recognizing an aberrant glycoform of human tissue inhibitor of metalloproteinase-1 (TIMP-1) using decoy immunization and phage display. , 2011, Journal of biotechnology.
[100] Sudhir Srivastava,et al. A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer , 2011, Cancer Prevention Research.
[101] Sudhir Srivastava,et al. Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens , 2011, Cancer Prevention Research.
[102] I. Jacobs,et al. The Sine Qua Non of Discovering Novel Biomarkers for Early Detection of Ovarian Cancer: Carefully Selected Preclinical Samples , 2011, Cancer Prevention Research.